A. Stuetz

发表

NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo

K. Mertz, S. Wagner, G. Stingl, 2013, PloS one.

Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.

W. Hoetzenecker, A. Elbe-Bürger, T. Kopp, 2005, The Journal of allergy and clinical immunology.

Inhibition of T‐cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof

A. Winiski, A. Stuetz, Shirley Wang, 2007, Experimental dermatology.

Binding of Pimecrolimus and Tacrolimus to Skin and Plasma Proteins: Implications for Systemic Exposure after Topical Application

A. Stuetz, A. Billich, T. Moenius, 2008, Drug Metabolism and Disposition.

Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid‐pretreated skin

A. Stuetz, A. Billich, H. Aschauer, 2005, Experimental dermatology.

Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.

A. Stuetz, J. Meingassner, M. Grassberger, 2001, Seminars in cutaneous medicine and surgery.

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.

K. Wolff, R. Oberbauer, J. Kehren, 2002, The Journal of investigative dermatology.

Ascomycins: promising agents for the treatment of inflammatory skin diseases

M. Graeber, C. Paul, A. Stuetz, 2000, Expert opinion on investigational drugs.

Pimecrolimus inhibits up‐regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells

J. Chung, F. Kalthoff, A. Stuetz, 2002, Clinical and experimental immunology.

Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice.

G. Kramer, A. Elbe-Bürger, G. Stingl, 2009, The Journal of investigative dermatology.

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.

W. Hoetzenecker, A. Elbe-Bürger, G. Stingl, 2004, The Journal of investigative dermatology.

Mechanical and metabolic injury to the skin barrier leads to increased expression of murine β-defensin-1, -3, and -14.

J. Schröder, K. Ahrens, A. Stuetz, 2011, The Journal of investigative dermatology.

Differential Inhibition of Primary versus Preactivated T Cells by Pimecrolimus but Not by Tacrolimus in vitro

A. Winiski, F. Kalthoff, A. Stuetz, 2006, International Archives of Allergy and Immunology.

Chemistry of the immunomodulatory macrolide ascomycin and related analogues.

A. Stuetz, M. Bulusu, K. Baumann, 2011, Progress in the chemistry of organic natural products.

Effect of pimecrolimus vs. corticosteroids on murine bone marrow‐derived dendritic cell differentiation, maturation and function

T. Luger, S. Grabbe, G. Varga, 2006, Experimental dermatology.

Pimecrolimus does not affect the differentiation, maturation and function of human monocyte‐derived dendritic cells, in contrast to corticosteroids

J. Chung, F. Kalthoff, A. Stuetz, 2003, Clinical and experimental immunology.

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

A. Aszódi, A. Stuetz, A. Billich, 2004, International journal of pharmaceutics.

Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of Pimecrolimus

K. Wolff, A. Stuetz, K. Baumann, 2006, International Archives of Allergy and Immunology.

Pimecrolimus for the treatment of inflammatory skin disease

K. Wolff, A. Stuetz, 2004, Expert opinion on pharmacotherapy.

Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis.

W. Hoetzenecker, A. Elbe-Bürger, G. Stingl, 2006, The Journal of investigative dermatology.

Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

M. Detmar, G. Bold, C. Halin, 2008, The American journal of pathology.

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.

Kristine Rose, Christopher Schuster, Hans Skvara, 2011, The Journal of investigative dermatology.

Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight.

A. Stuetz, A. Billich, F. Schmook, 2005, Bioorganic & medicinal chemistry.

SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7

A. Winiski, A. Stuetz, Shirley Wang, 2014, Experimental dermatology.

Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes.

R. Gallo, A. Stuetz, J. Schauber, 2008, The Journal of investigative dermatology.

Partnership among dermatology, the Society for Investigative Dermatology, and industry: suggestions for change.

A. Stuetz, 2007, Journal of Investigative Dermatology.

fc24 Lde225, a specific smoothened inhibitor, for the topical treatment of nevoid basal cell carcinoma syndrome (gorlin's syndrome)

G. Stingl, F. Kalthoff, A. Stuetz, 2010 .

Development of a cellular assay as a personalized model for testing chronic wound therapeutics.

T. Luger, A. Stuetz, G. Restivo, 2024, Journal of Investigative Dermatology.